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Post 5-fluorouracil-treated  murine bone marrow cells infected with a recombinant retrovirus (murine 
stem cell virus-interleukin 11 [MSCV-IL-11]) bearing a human IL-11 gene were transplanted 
into lethally irradiated  syngeneic mice. Analysis of proviral integration sites in DNA prepared 
from hematopoietic tissues and purified cell populations  of long-term reconstituted primary and 
secondary recipients demonstrated polyclonal engraftment by multipotential stem cells. High 
levels (100-1,500 U/ml) of IL-11 were detected in the plasma of the MSCV-IL-11 mice. Systemic 
effects of chronic IL-11 exposure included loss of body fat, thymus atrophy,  some alterations 
in plasma protein levels, frequent inflammation of the eyelids, and often a hyperactive state. A 
sustained rise in peripheral platelet levels (•l.5-fold)  was seen throughout the observation period 
(4-17 wk). No changes were observed in the total number of drculating leukocytes in the majority 
of the transplanted  animals (including 10 primary and 18 secondary recipients) despite a >20- 
fold elevation in myeloid progenitor cell content in the spleen. The exceptions were members 
of one transplant pedigree which presented with myeloid leukemia during the secondary transplant 
phase. A clonal origin of the disease was determined, with significant expansion of the MSCV- 
IL-11-marked clone having occurred in the spleen of the primary host. Culturing of leukemic 
spleen cells from a quaternary recipient led to the establishment of a permanent cell line (denoted 
PGMD1). IL-11-producing PGMD1 myeloid leukemic cells are dependent on IL-3 for continuous 
growth  in  vitro  and  they differentiate  into  granulocytes  and  macrophages  in  response  to 
granulocyte/macrophage  colony-stimulating factor. The inability of autogenously produced IL-11 
to support autonomous growth of PGMD1 cells argues against a mechanism of transformation 
involving a classical autocrine loop. 
I 
nteraction between hematopoietic and stromal cells in the 
bone marrow is important for the maintenance of steady- 
state hematopoiesis (1). IL-11 is a recently identified multifunc- 
tional stromal cell-derived factor whose actions on cells of 
the hematopoietic and immune systems implicate it as a poten- 
tial contributor to this process (2). 
A cDNA encoding IL-11 was originally isolated from the 
PU-34 primate bone marrow stromal cell line based on an 
activity in the culture supernatant that stimulated the prolifer- 
ation of IL-6-dependent Tl165 routine plasmacytoma cells 
(3, 4). The identification of IL-11 through the use of an IL-6 
bioassay prompted the testing of this cytokine in other IL-6- 
responsive systems. The results of these studies have confirmed 
that IL-11 and IL-6 possess overlapping biologic properties. 
Like IL-6, IL-11 has megakaryocytopoietic  and thrombopoietic 
functions (4-8). In addition, IL-11 has been shown to syner- 
gize with IL-3, IL-4, or the ligand for the c-kit receptor to 
promote the growth of blast colony-forming cells (CFC) l, 
an effect previously described for IL-6 and G-CSF (9-11). IL- 
11 also shares with IL-6 the ability to augment antigen-specific 
antibody responses (12). Outside the hematopoietic system, 
activities common to both IL-11 and IL-6 have been described 
on hepatocytes, preadipocytes, and neuronal cells (13-16). 
There have been a limited number of reports of in vivo 
effects of IL-11 on hematopoiesis.  Administration of IL-11 
to mice accelerated platelet and neutrophil recovery after bone 
1 Abbreviations used in thispaper: CFC, colony-forming cells; LIF, leukemia 
inhibitory factor; MSCV, routine stem cell virus;  neo, neomycin phos- 
photransferase; pgk, phosphoglycerate  kinase. 
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ment of normal mice with IL-11 resulted in modest increases 
in peripheral platelet levels above those of vehicle-treated con- 
trols (*1.3-fold) with minimal effects noted on circulating 
neutrophil numbers (8, 17, 18). These findings are comparable 
to those obtained by in vivo administration of IL-6 (19-21), 
but contrast sharply with the striking changes we observed 
in mice chronically exposed to high plasma concentrations 
of IL-6 after engraftment with bone marrow cells constitu- 
tively expressing a retrovirally introduced IL-6 gene (22). The 
IL-6 transplant mice uniformly  developed a fatal myeloprolifer- 
ative syndrome characterized by neutrophil excess (up to 400 
￿  103 cells/mm3), microcytic anemia, thrombocytosis fol- 
lowed by thrombocytopenia, and marked alterations in plasma 
protein levels. In general, these hematologic changes were 
greater than had previously been seen in other IL-6 animal 
models (23,  24).  Thus, in the present study, we used our 
retroviral delivery system to examine the long-term hemato- 
logic consequences of dysregulated IL-11 expression. 
Materials and Methods 
Murine Stem Cell Virus (MSCV)-IL11 Retrovirus Vector and Cell 
Lines.  The MSCV-IL-11 vector (see Fig. 1 A) was constructed by 
inserting a 0.8-kb EcotLI-BgllI fragment of a human Ib11 cDNA 
(4) into the corresponding sites of the polylinker in the MSCV 
vector (version 2.1 has unique EcoRI, HpaI, XhoI, and BglII sites) 
(22). The salient  features  of the MSCV vector design  include  variant 
LTRs and modified 5' untranslated sequences conferring efficient 
LTR-directed expression in primitive cells, an extended packaging 
region (~ +) for high viral titer containing mutations that abolish 
the synthesis  of  any gag-related  polypeptides  and eliminate the need 
for splicing to express inserted genes, and the absence of all enve- 
lope sequences, thereby abrogating the possibility of homologous 
recombination with corresponding sequences of endogenous retro- 
viruses. The neomycin  phosphotransferase  (neo) gene in MSCV v2.1 
contains a synthetic initiation sequence favorable for translation 
in mammalian cells and has been placed under the transcriptional 
control of an internal phosphoglycerate  kinase (pgk) promoter for 
constitutive expression in a wide range of cell types (25). Plasmids 
were constructed using standard techniques (26). 
Recombinant virus was produced from clones of GP+E-86 
ecotropic helper-free packaging calls (27), generated as described 
previously  by infection of tunicamycin-treated cells with superna- 
tant from transient transfectants  (22). The cell line used for all gene 
transfer experiments, GP+E-86/MSCV-Ib11 c3, produces struc- 
turally intact MSCV-Ib11 virus with a titer of 4  x  106 G418- 
resistant CFU/mlwhen assayed  on NIH3T3 fibroblasts. Cells were 
maintained in DME with 4.5 g/1 glucose (GIBCO BILL,  Gaithers- 
burg, MD) supplemented with 10% calf serum (Hyclone Labora- 
tories, Logan, UT) in a humidified atmosphere containing 5% 
CO2 at 37~ 
Retrovirus Infection and Transplantation of Bone Marrow.  Female 
BALB/c  mice (Charles River Laboratories, Montreal, Canada) were 
used at 6-8 wk of age as bone marrow donors and recipients. Bone 
marrow processing, infection, and transplantation were carried out 
according to established  procedures (22, 28). In brief, bone marrow 
was flushed from hind limbs of donors injected 4 d previously  with 
150 mg/kg 5-fluorouracil  (Hoffmann-La  Roche Ltd., Mississauga, 
Canada) with ice-cold IMDM containing 50/~M 2-ME and 10% 
heat inactivated FCS (GIBCO BILL). After erythrocyte lysis in 
0.17 M ammonium chloride, nucleated  cells  were added to 100 mm 
petri dishes (Fisher Scientific  Co., Pittsburgh, FA) at a density of 
5  x  10  s cells/ml in IMDM supplemented with 50/~M 2-ME, 
10% heat-inactivated  FCS, 10% conditioned medium from X630- 
rlL3 cells (a source of IL-3; a gift of F. Melchers, Basel, Switzer- 
land) (29), and 10% conditioned medium from Sp2/mlb6 cells 
(a source of Ib6) (30). After 48 h, the bone marrow cells were 
collected and added to  subconfluent monolayers of GP+E-86/ 
MSCV-Ib11 c3  cells in  lO0-mm tissue culture  dishes (Nunc, 
Roskilde, Denmark)  at a density of 5  x  10  s cells/ml in fresh 
medium supplemented with 8/~g/ml polybrene. After a further 
48 h, nonadherent bone marrow cells were harvested  and incubated 
in cocultivation medium containing 0.75 mg/ml (actual concen- 
tration) G418 (GIBCO BRL). These calls  were collected 24 h later 
and injected via the tail vein into recipients that had received 7 
Gy of  irradiation (gammacell  1000; Atomic Energy of  Canada Ltd., 
Kanata, Ontario, Canada). Each mouse received  between 5 x  10  s 
and 2 x  106 ceils (seven donor equivalents  per recipient). For serial 
transplantations, 10  6  bone marrow cells from affected  animals  were 
injected intravenously  into lethally  irradiated  (7 Gy) recipients. Mice 
were housed one to four per sterilized  microisolator  cage on laminar 
flow racks. The colony was periodically  tested for a panel of  viruses 
by analysis  of serum samples (Charles River Laboratories  Diagnostic 
Services, Wilmington, MA). Animals tested negative for sendai 
virus, pneumonia virus of mice, mouse hepatitis virus, minute virus 
of mice, mouse polio virus and reovirus type 3. The animals were 
also found to be free of mycoplasma. 
Hematologic and Pathologic Analysis.  Blood was collected from 
the retroorbital sinus at weekly/biweekly intervals after transplant 
and immediately  before death. Total leukocytes,  total erythrocytes, 
hemoglobin, hematocrit, mean corpuscular volume, mean corpus- 
cular hemoglobin, mean corpuscular hemoglobin concentration, 
red cell  distribution width, total phtelets, and mean platelet volume 
were determined  on a System  9000 Hematology Series Cell Counter 
(Serono-Baker Instruments, Allentown, PA) equipped with a vet- 
erinarian software package (22). Controls were mice transplanted 
with hematopoietic  cells infected  with other MSCV viruses as well 
as age-matched littermates. 
Mice were killed by cervical dislocation and necropsy examina- 
tions were performed immediately after death. Tissues were pre- 
served in 10% neutral-buffered  formalin overnight, then embedded 
in paraffin, sectioned, and stained with hematoxylin and eosin be- 
fore examination by light microscopy (22). Tissues examined in- 
cluded spleen, thymus, lungs, heart, liver, pancreas, stomach, in- 
testines, kidneys,  lymph nodes, sternum (bone marrow), and eyelids. 
In Vitro Progenitor  Cell Assay.  The number of CFC was deter- 
mined by plating nucleated bone marrow (at 104 and 2  x  104 
cells/ml) and spleen calls (at 2  x  104 and 4  x  104 cells/m1) in 
duplicate 1-ml cultures (35-ram Lux suspension plates; Nunc, Inc., 
Naperville, IL) containing cx-MEM, 0.8% methylcellulose, 30% 
FCS, 1% BSA, 100/~M 2-ME, 3 U/ml erythropoietin, and 1% 
FWM-stimulated spleen conditioned medium (a source of  IL-3 and 
GM-CSF; Terry Fox Laboratory, Vancouver, Canada) as described 
(31). Where indicated, G418 was added to a final concentration 
of I mg/ml. Colonies (consisting of more than 50 cells) of granu- 
locytes, macrophages, erythroid cells, and mixtures of these with 
megakaryocytes  were enumerated using an inverted microscope  on 
day 7 and recorded together as CFC. 
Isolation of  Primary Cdl Populations.  To generate populations en- 
riched for mast cells (adherent and nonadherent), bone marrow 
or spleen cells were cultured in 100-mm tissue culture dishes in 
IMDM supplemented with 50/zM 2-ME, 10% heat-inactivated 
FCS, 10% conditioned medium from X630-rIL3 cells, and 0.75 
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pared by culturing bone marrow or spleen cells for 48 h in IMDM 
supplemented with 50 #M 2-ME, 10% heat-inactivated  FCS, 10% 
conditioned medium from X630-rlL3 calls, and 20% conditioned 
medium from L929 cells (a source  of  CSF-1), transferring  the nonad- 
herent cells  to dishes  containing IMDM supplemented  with 50 #M 
2-ME, 10% heat-inactivated  FCS, 30% conditioned medium from 
L929 cells, and 0.75 mg/ml G418, and culturing for periods of 
up to 4 wk. T cell populations were obtained by culturing spleen 
cells in tLPMI 1640 medium (GIBCO BILL) supplemented with 
50 #M 2-ME, 10% heat-inactivated  FCS, 10% conditioned  medium 
from X630-rIL2 ceils (a source of IL-2; a gift of F. Melchers) (29), 
10% conditioned medium from X630-rlL4 ceils (a source of Ib4; 
a gift ofF. Melchers) (29), 5 #g/m1 Con A, and 0.75 mg/ml G418 
for more than 3 wk. The various cell populations were judged to 
be >90% pure  by cytochemical  and immunological  criteria (32, 33). 
Bioassays.  IL-11 activity in culture supernatants and plasma 
samples was detected by T10 microproliferation assay (a gift of F. 
Bennett,  Genetics Institute)  (34). The cells were propagated in 
ILPMI 1640 medium supplemented with 50/zM 2-ME, 10% heat- 
inactivated FCS, and 20 U/m1 recombinant human IL-11. Purified 
recombinant human Ib11 (a gift of P. Schendel, Genetics Insti- 
tute) was produced in Escherichia coli and had asp act of 2.5  x 
104 U/mg protein. For the assay, T10 cells were harvested by cen- 
trifugation, washed twice in medium lacking IL-11, and then used 
at 104 cells/200 #1 well in the presence of twofold dilutions of 
samples to be tested. Cells were labded with 0.2 #Ci [3H]TdK 
(New England Nuclear, Boston, MA) from 48-56 h. The incorpo- 
rated radioactivity was determined for triplicate cultures by liquid 
scintillation counting (betaplate; Walhch, Gaithersburg, MD) after 
transfer of cellular debris to glass fiber filters with a cell harvester 
(Skatron Inc., Sterling, VA). The standard deviation of means of 
triplicate cultures was always  <15%. Each assay  was standardized 
with recombinant human Ibll and values (U/ml) were calculated 
by probit analysis. 1 U/ml of Ibll is the amount that induces half- 
maximal [3H]TdR incorporation. When included, 1/100 dilution 
of a rat mAb against murine IL-6 (a gift of L. Sachs, Weizmann 
Institute, Rehovot, Israel) (35) completely  neutralized IL-6-induced 
proliferation of T10 cells. 
IL-6 activity  in plasma samples  was tested for by B9 microprolifer- 
ation assay (36) essentially as described (22). 
Microwell cultures of 32D and OTT1 cells were similarly used 
to assay IL-3 and GM-CSF as described (37). OTT1 murine my- 
eloid cells which are dependent for their survival and proliferation 
on one of IL-3, GM-CSE or IL-5 were obtained from primary cul- 
tures of murine bone marrow infected with a retrovirns vector car- 
rying a murine IL-lot cDNA and the bacterial neo gene (33). The 
subdone (c12) used is propagated in IMDM supplemented with 
50 #M 2-ME, 10% heat-inactivated FCS, and 10% conditioned 
medium from X630-rIL3 cells" murine Pam 212 keratinocyte cells 
(a source of GM-CSF; a gift of R. McKenzie and D. Sauder, Sun- 
nybrook Health Science Centre) (38) or X630-rlL5 calls (a source 
of IbS; a gift of F. Melchers) (29). 
Cellulose Acetate Electwphoresis  of  Plasma Samples.  Electrophoretic 
separations of plasma proteins were performed in barbital-sodium 
barbital buffer according  to the manufacturer's  instructions (Sepratek 
System; Gelman ,Sciences, Inc., Ann Arbor, MI). Briefly,  electropho- 
resis was for 20 min at 225 V on cellulose acetate strips soaked 
in the buffer for 10 min before sample application. After electropho- 
resis, the strips were stained and fixed for 10 min in 0.5% Ponceau 
S/7.5% trichloroacetic  add, destained  for 15 rain in 5% acetic  add, 
and cleared in 40.0% aqueous N-methyl pyrrolidone before pho- 
tography. 
Nucleic Acid Analysis.  Southern  and Northern blot analyses were 
carried out according to standard procedures (26). High molecular 
weight DNA (10 #g) was digested with EcoRI (which cleaves 
uniquely within the vector) and proviral  junction fragments were 
identified by Southern blotting using a 1.0-kb BgllI-SmaI frag- 
ment of the neo gene as probe (39). Total cellular (10 #g) or 
poly(A)  + (1 #g) KNA was analyzed by Northern blotting for 
viral RNA transcripts using a 0.8-kb EcoRI-BgllI fragment of a 
human IL-11 cDNA (4) and a 1.0-kb BgllI-SmaI fragment of the 
neo gene as probes. Endogenous IL-6  transcripts were detected with 
a probe consisting of a 0.6-kb EcoRI-BglII fragment of a murine 
IL-6 cDNA (40). Other probes used were restriction fragments ob- 
tained from the following plasmids: p17.4 (carrying a cDNA en- 
coding the murine Mac-1 ~2 integrin subunit; 63056; American 
Type Culture Collection, Rockville, MD [ATCC]); K4-1.1 (car- 
rying a murine intercellular  adhesion  molecule 1 (ICAM-1)  cDNA; 
63043, ATCC); pMC1 (carrying murine c-myb  genomic sequences; 
41056, ATCC); pSVc-mycl (carrying the second and third exons 
of the murine c-myc gene; 41029, ATCC); and p465.20 (carrying 
a murinejunB cDNA; 63025, ATCC). The amount and integrity 
of  RNA loaded  was monitored by hybridization  with a probe recog- 
nizing glyceraldehyde-3-phosphate  dehydrogenase  sequences (41). 
Results 
Infection of lL-6-dependent B Cell Lines.  The T10 cell line 
is a derivative of the IL-6-dependent Tl165 plasmacytoma 
that wiU also grow in medium supplemented with IL-11 (34). 
To demonstrate MSCV-IL-11-encoded production of func- 
tional IL-11, T10 cells were infected by exposure to helper- 
free recombinant virus produced by a donal isolate of GP+ E-86 
packaging cells and examined for conversion to factor-inde- 
pendent growth. IL-6-dependent murine B9 hybridoma cells 
(36) were also infected with MSCV-IL-11 since testing of 
several factor-dependent cell lines revealed IL-11 to have mito- 
genie activity for these ceUs (our unpublished results). G418- 
resistant populations of MSCV-IL-11-infected  T10 ceils were 
readily established  and could be maintained in the absence 
of an exogenous source of IL-11, indicating successful trans- 
mission of functional vector sequences. Notably, G418-resistant 
populations of MSCV-IL-11-infected B9 ceils were also con- 
verted to growth factor autonomy. Conditioned medium pre- 
pared from culture supematants ofT10 and B9 infectants sup- 
ported the long-term growth of T10 cells. Northern blot 
analysis of poly(A) §  RNA from infectants with an IL-11 
probe revealed, as expected, a 3.6-kb transcript originating 
from the MSCV-IL-11 LTK (Fig.  1 B). Rehybridization of 
the blot with a routine IL-6 probe failed to detect any en- 
dogenous IL-6 mKNA species  (Fig.  1 B).  To  investigate 
whether autogenous IL-11 synthesis could facilitate in vivo 
growth of IL-6-dependent ceils, syngeneic BALB/c mice were 
inoculated subcutaneously (106 cells/site)  with pools of in- 
fectants and corresponding parental cell lines. As shown in 
Table 1, compared to parental T10 ceils, T10 infectants formed 
tumors at a much higher frequency and with a much shorter 
latency period. The in vivo growth potential of IL-6-depen- 
dent B9 cells (42) was also enhanced by constitutive IL-11 
synthesis. MSCV-IL-11-infected  B9 ceils exhibited a decreased 
latency period of tumor development that was comparable 
1177  Hawley  et al. Table  1.  Tumorigenicity of MSCV-IL-11-infected B  cells 
Cells  Latency period  Tumor take  Tumor weight 
d  g 
T10/IL-11  11"  10/10  1.1  +  0.2 
T10  62  4/10  0.8  +  0.5 
B9/IL-11  11  10/10  1.1  _+  0.3 
B9/IL-6*  11  10/10  1.0  +  0.4 
B9  16  10/10  0.7  _+  0.3 
BALB/c mice  (6-8 wk of age) were inoculated  subcutaneously  with 106 
cells of the indicated  cell  lines  and pools of  infectants;  two sites per mouse. 
" Time after injection when animals were killed. 
*  Pool of IL-6-independent derivatives of B9 cells created by infection 
with the L6PNL retrovirus bearing a murine IL-6 gene (32). 
Figure  1.  Schematic  representation  of the MSCV-IL-11  retrovirus  vector 
and its expression in Ib6-dependent B cell lines. (A) The Ibll gene in 
MSCV-Ib11 is transcribed  from the retroviral  LTR as a 3.6-kb transcript 
which also contains  neo sequences; the neo gene is transcribed  from the 
pgk promoter as a 1.4-kb mRNA. Also indicated  is the extended  pack- 
aging region (~+) for high viral titer and the modified  5' untranslated 
region (tRNA c~") which facilitates  LTR-directed  transcription  of exoge- 
nous genes in primitive cells. Restriction sites: (Bg) BgllI; (E) EcoRl; 
(N) NheI; (P) polylinker  (BamHI,  SalI, HindlII,  and ClaI). See Materials 
and Methods for details. (B) Northern blot analysis  of poly(A)  + R.NA 
(1 #g) from pools of MSCV-Ibll-infected  T10 and B9 cells showing  ab- 
sence of the endogenous 1.3-kb IL-6 mRNA. Other RNAs were from 
Sp2/0 hybridoma  cells infected  with MSCV-IL-11,  parental B9 cells, and 
OTT1 murine  myeloid  cells. Sizes  were  determined  by comparison  to 28S 
and 18S rR.NAs (4.5 and 1.8 kb, respectively). 
with that observed  for B9 derivatives  producing autocrine 
retrovirally encoded IL-6. Collectively, the results show that 
IL-11 can act as an autocrine growth factor for certain IL-6- 
dependent murine B cell lines via a mechanism that does not 
involve  endogenously synthesized IL-6. 
IL-11 Expression  in Long-Term Reconstituted  Mice.  Lethally 
irradiated BALB/c mice received intravenous inoculations of 
MSCV-IL-11-infected bone marrow cells (106 cells) according 
to a protocol previously used (22) to generate transplant mice 
having excessive circulating levels of IL-6. Plasma obtained 
from all primary and secondary MSCV-IL-11 mice examined 
5-16 wk after transplantation, but not from control mice, 
exhibited significant activity in the T10 bioassay (mean values 
of 500  U/ml  IL-11  equivalents;  range,  100-1,500  U/ml; 
n =  10). The T10 stimulatory activity could not be inhibited 
by a neutralizing antibody to murine IL-6 (Fig. 2 top). This 
finding plus the fact that plasma from both MSCV-IL-11  and 
control mice had minimal stimulatory activity when assayed 
on IL-6-dependent B9 cells (<0.1 ng/ml IL-6) ruled out the 
possibility that the T10 response  was mediated by endoge- 
nous IL-6. Recent experiments demonstrating >90%  inhi- 
bition of plasma-induced T10 proliferation by a neutralizing 
anti-IL-11  antibody (a gift of E. Alderman, Genetics Insti- 
tute) have established the identity of the active species as IL- 
11  (data not shown). 
Northern blot analysis of total spleen RNA demonstrated 
sustained expression  of the 3.6-kb viral IL-11 mRNA for 
periods of up to 16 wk in secondary recipients (Fig.  3 A). 
No endogenous IL-6 mRNA transcripts were detected upon 
rehybridization of the blot with a probe specific for murine 
IL-6 coding sequences  (Fig.  3 A). 
The clonal composition of the reconstituted hematopoi- 
etic systems of MSCV-IL-11 transplant mice was examined 
by Southern blot analysis of EcoRI-digested DNA with a 
neo probe. Since EcolLl cleaves  the MSCV-IL-11 provirus once 
(Fig.  1 A), each band represents  a unique integration site. 
As illustrated in Fig. 3 B, genomic DNAs from hematopoi- 
eric  tissues  (bone marrow and spleen)  and purified G418- 
resistant cell populations (macrophages, mast cells and T cells) 
of a representative primary recipient (mouse 96, reconstituted 
for 12 wk) and two secondary recipients (mice 95.1 and 95.2, 
reconstituted for 12 wk with bone marrow from a primary 
mouse reconstituted for 16 wk) contained many fragments 
that hybridized to the neo probe. The presence of common 
bands in lanes containing DNA samples from lymphoid and 
myeloid lineage cells, as well as bands identifiable in only some 
of the lanes, indicated polyclonal repopulation by primitive 
MSCV-IL-11-infected hematopoietic cells, a subset of  which 
were multipotential stem cells. 
1178  Dysregulated  IL-11 Expression in Mice Figure 2.  Plasma analyses  of MSCV-Ibll mice. (Tbp)  Plasma was tested 
for Ibll activity in the T10 proliferation assay in the absence or presence 
of a neutralizing  antibody  to routine II.-6  (anti-Ib6  mAb; dilution 1/100). 
Results are presented for 1% final concentrations of plasma collected be- 
fore death.  Values plotted are the mean and SE of three determinations. 
The numbers designate individual animals: mice 74, 77, and 96 are pri- 
mary recipients; mice 77.1, 95.1, and 95.2 are secondary recipients. (Dashed 
line) Maximal proliferation of T10 cells to purified recombinant human 
IL-11 (56,680 +_ 2,670  cpm). Representative  T10 responses to ILll (5 U/ml) 
and II~6 (10% conditioned medium from Sp2/mlL-6 cells) are shown. 
(Bottom) Cellulose acetate electrophoresis of plasma obtained from mice 
73 and 77.1 revealing alterations in levels of albumin (Alb) and protein(s) 
in the oll-(top arrow) and or2- (bottom arrow) regions by comparison with 
the protein patterns of normal BALB/c (Ba) and transplant  (mouse 54) 
controls  (Co).  Note that whereas the qualitative changes are similar to 
those observed in mice 31 and 41 overexpressing II~6 (22), there are quan- 
titative differences. (Ig) Immunoglobulin  fraction. 
Hematologic Changes in MSCV-IL-11 Transplant  Mic~  The 
main consequence of persistent IL-11 expression was a sus- 
tained rise in platelet levels (1.5-1.6-fold higher than corre- 
sponding values obtained for normal and control transplant 
mice, respectively) throughout the observation period (Table 
2; Fig. 4). Since this increase could not be attributed to IL-6, 
the possibility was considered that IL-11 may have induced 
elevations of IL-3 or GM-CSF, two factors with known in 
vivo actions on megakaryocytes (43, 44). However, no IL-3 
or GM-CSF activity was detectable by 32D or OTT1 micro- 
proliferation assays (33, 37) in the plasma of any mice tested. 
On the basis of results from in vitro studies (4-6),  the ob- 
served changes in platelet levels might be due in part to IL-11 
acting in collaboration with low amounts of these factors. 
To  address  this  issue,  current  experiments are  examining 
cytokine gene  mRNA  profiles  in  MSCV-IL-11  mice by 
RT-PCR. 
Long-term exposure to  high circulating levels of IL-11 
resulted in minimal changes in other peripheral blood cell 
values (Table 2). Differential leukocyte counts showed a neu- 
trophilic predominance (mean, 70%) but there was no in- 
crease in total leukocyte numbers. Although in vitro erythro- 
poietic properties of IL-11 have been recognized (45), the in 
vivo effects of IL-11 on circulating erythrocyte values were 
minor. In fact, hematocrits were slightly reduced compared 
with those of normal mice because of a small decrease in mean 
corpuscular volume. The significance  of this is unknown, how- 
ever, since hematocrit values did not differ meaningfully  from 
values obtained for control transplant mice. 
In view of the relatively normal peripheral blood cell counts 
in MSCV-IL-11 mice, it was notable that enhanced hemato- 
poiesis was observed in bone marrow and spleen (Fig.  5). 
This was most striking in the case of the spleen where there 
was a concomitant 12-56-fold elevation in total progenitor 
cell content (Table 3). As spleen weight was increased about 
twofold (Table 3), the actual total increase per spleen in pro- 
genitor cell numbers was 20-100-fold. Detailed cytological 
analyses of colonies formed in  methylcellulose-containing 
medium were not carried out, but no conspicuous  differences 
between MSCV-IL-11 and control mice in the relative distri- 
bution of the various progenitor subpopulations were apparent 
upon gross inspection of cultures. Although high percentages 
(31-68%) of CFC found in the spleens of both primary and 
secondary recipients were G418 resistant  (Table 3), substan- 
tial expansion of G418-sensitive  progenitors also occurred, 
indicating that  paracrine  mechanisms contributed  to  the 
phenomenon. Associated with the general rise in splenic he- 
matopoiesis was a minor elevation in spleen megakaryocyte 
numbers in correspondence with the higher blood platelet 
levels. 
Other Effects of  Dysregulated IL-11 Expression.  A uniform 
finding in MSCV-IL-11 mice was a 15-20% reduction in body 
weight (Table 3), often accompanied by a hyperactive state. 
Upon autopsy, it was observed that the decrease  in body weight 
was due to the loss of subcutaneous and intraabdominal fat, 
an effect presumably of the lipoprotein lipase inhibitory ac- 
tivity of IL-11 (14, 15). MSCV-IL-11  mice routinely devel- 
oped inflammatory eyelid lesions  characterized  grossly by 
marked swelling and erythema. Histologic analysis revealed 
acute inflammation on the surface of the conjunctival mucosa. 
Other consistent changes included thymus atrophy and fre- 
quent distention of the stomach or bowel with noticeable 
alterations in muscle tone. No significant changes were noted 
in liver or kidney and histologic examination of these organs 
failed to reveal any abnormalities. 
Cellulose acetate electrophoresis of plasma samples from 
MSCV-IL-11  mice revealed changes in acute phase protein 
levels, including slight reductions in albumin levels with in- 
creases in protein levels in the ol2-macroglobulin/haptoglobin 
region, that were much less pronounced than those observed 
in mice overexpressing  IL-6 (Fig.  2, bottom). Measurement 
of amounts of plasma proteins by rocket immunoelectropho- 
resis (46) indicated that albumin levels were in the normal 
range whereas haptoglobin levels were significantly  higher 
1179  Hawley et al. Figure 3.  Expression and distribution of MSCV-IL-11 proviruses in hematopoietic  tissues of long-term reconstituted  mice. (A) Total spleen RNA 
(10/zg) was examined by Northern blot analysis for the presence of viral IL-11 (top) and endogenous  Ib6 (middle) transcripts.  Hybridization of the 
blot with a probe specific  for glyceral&hyde-3-phosphate  dehydrogenase (GAPDI-I) indicated that similar amounts of RNA were loaded (bottom). Samples 
were from primary (mice 75, 77, and 95), secondary (mice 94.1 and 94.2), and tertiary (mouse 74.2.2) recipients. Spleen KNA from a secondary recipient 
of MSCV-Ib6-infected  bone marrow (mouse 31.1; reference 22) was inchded as a positive control for Ib6 sequences. (B) Proviral integrants were 
enumerated in EcoRI-digested DNA from various hematopoietic tissues and cell lineages by Southern blotting with a neo probe. Analyses of mouse 
95 and its secondary recipients (mice 95.1 and 95.2) and mouse 96 are presented. DNA (10/~g) was from the following tissues and ceil populations: 
(BM) bone marrow;  (BM Mr  bone marrow-derived  macrophages; (BM MAST) bone marrow-derived  mast cells; (LN) lymph node; (SPL) spleen; 
(SPL MF) splenic-derived macrophages; (SPL MAST) splenic-derived mast cells; and (SPL T) splenic-derived T cells. (Arrows) Proviruses common 
to myeloid and lymphoid lineages. 
Table  2.  Hematologic Values in MSCV-IL-I 1  Transplant Mice 
Hematologic  BALB/c  MSCV-X  MSCV-IL-11 
parameter  (n  --  42)  (n  =  28)  (n  =  43) 
WBC  (x 103/mm3)  *  9.0  +  3.0  7.6  _+  2.1  7.7  _+  2.4 
RBC  (x 106/ram  3)  10.6  _+  0.5  10.1  +  0.8  11.0  _+  0.6 
HGB  (g/dl)  16.3  _+  0.8  16.0  _+  1.2  15.6  _+  1.0 
HCT  (%)  49.2  _+  2.5  45.5  _+  3.4  44.0  _+  3.2 
MCV  (fl)  46.2  _+  0.8  45.1  +_  1.4  39.8  _+  1.4 
MCH  (pg)  15.4  _+  0.6  15.8  _+  0.7  14.1  _+  0.7 
MCHC  (g/dl)  33.3  _+  1.5  35.1  _+  1.2  35.5  _+  1.4 
RDW  (%)  22.7  _+  0.8  21.8  +  0.8  22.8  _+  0.6 
PLT  (x 103/mm  3)  1,200  _+  124  1,097  _+  131  1,811  _+  192 
MPV  (fl)  4.7  _+  0.6  5.4  _+  0.5  4.7  _+  0.4 
Data recorded are the mean and SE of values. MSCV-IL-11 data were obtained from analysis of three primary recipients (mice 94, 95, and 96) and 
four secondary recipients (mice 94.1, 94.2, 95.1, and 95.2) at intervals 4-16 wk after transplant. MSCV-X data were obtained from similar analysis 
of six primary recipients of bone marrow infected with other MSCV constructs.  BALB/c data were obtained from analysis of 42 normal mice (8-12 
wk of age). 
* WBC, total lenkocytes; RBC, total erythrocytes;  HGB, hemoglobin; HCT, hematocrit;  MCV, mean corpuscular volume; MCH, mean corpuscu- 
lar hemoglobin; MCHC, mean corpuscular hemoglobin concentration; RDW, red cell distribution width; PLT, total platelets; MPV, mean platelet 
volume. 
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Figure 4.  Elevated  platelet levels  in MSCV-IL-11  mice. Platelet analyses 
were performed  as described  in Material and Methods on peripheral blood 
collected at the time points indicated after bone marrow transplantation. 
Platelet counts for representative primary (mice 94, 95, and 96) and sec- 
ondary (mice 94.1, 94.2, 95.1, and 95.2) recipients are presented. Platdet 
counts of control transplant mice stabilized  by 4 wk after transplantation 
and were slightly lower than normal BALB/c  values (range, dashed  lines). 
See Table 2 for values of all hematologic parameters examined. 
(mean values of 9.4/~g/ml;  range,  7.2-11.0/xg/ml;  n  --  8) 
than  normal  (<1/zg/ml).  These results indicate that  IL-11 
can function as a regulator of the hepatic acute phase response 
in  mice  (13). 
Myeloid Leukemia Development after Serial Transplantation  of 
MSCV-IL-11-infected Hematopoietic Cells.  6 wk after trans- 
plantation with bone marrow cells from mouse 74, decreased 
platelet levels were detected in two secondary recipients. By 
8 wk, both animals  were severely thrombocytopenic (platelet 
counts  ",q30  x  103/ram3).  One mouse (mouse  74.1)  had 
lower than normal peripheral leukocyte counts (3.6  x  103/ 
mm  3) whereas the other animal (mouse 74.2) presented with 
leukocytosis  (43.6  x  103/mm3).  At  necropsy,  both  mice 
were found  to  have  considerably enlarged  spleens  (spleen 
weights of 0.364 and 0.498 g). Bone marrow (2  x  106) or 
spleen (5  x  106) cells from these mice were leukemogenic 
within 4 wk of transplant into sublethally irradiated (4.5 Gy) 
tertiary recipients.  The characteristic features of the malig- 
nant disease included leukocytosis with neutrophil bias (>200 
x  103 cells/mm  3)  and evidence of blasts  in  the peripheral 
blood, anemia (mean hematocrits, 27%), thrombocytopenia 
(mean  platelet  counts,  56  x  l(P/mm3),  and splenomegaly 
(mean spleen weights,  0.65 g).  Histopathologic analysis  of 
the spleen from diseased mice showed effacement of the splenic 
architecture  by cytologically abnormal  cells  (Fig.  6 B). 
Attempts to establish factor-dependent or autonomously 
growing cell lines in liquid culture from spleen ceils of ter- 
tiary 74-series recipients were unsuccessful. However, in vitro 
culture of spleen cells from one quaternary recipient (mouse 
74.1.1.1) yielded an IL-11-producing yet IL-3-dependent cell 
line  (denoted  PGMD1,  Fig.  6  C).  An  immature  myeloid 
phenotype was determined by flow cytometric analysis of cell 
Figure  5.  Histology  of bone marrow and 
spleen of MSCV-Ibll mice. (.4) Normal bone 
marrow (xg00). (B) Hyperphstic  bone  marrow 
of mouse 95  (x900). (C)  Normal spleen 
(x 450). (D) Spleen of mouse 96 showing ex- 
pansion of red pulp with myeloid dements 
(￿ 
1181  Hawley  et al. Table  3.  Progenitor  Cell Changes in MSCV-IL-I1  Transplant Mice 
CFC in  CFC in 
Time of  Body  Spleen  bone marrow  spleen 
Mouse  reconstitution  weight  weight  (%G418K)  (%G418R) 
wk  g 
73.1"  17  16.7  0.098  5,600  (52)*  900 (56)* 
73.2  10  ND  0.170  4,250  (45)  2,500  (47) 
74  12  17.0  0.260  5,750 (51)  3,900  (58) 
75  12  16.6  0.170  5,000  (55)  3,300  (33) 
76  7  ND  ND  5,350  (50)  4,800  (52) 
77  11  ND  ND  5,500 (48)  2,000  (38) 
77.1  5  17.5  0.200  8,500  (50)  2,900  (68) 
78  9  ND  0.180  6,000  (54)  1,750 (64) 
79  9  ND  ND  5,000  (36)  2,250  (37) 
94  16  ND  0.170  5,600 (47)  1,860 (61) 
94.1  16  ND  0.175  15,000 (50)  4,000  (50) 
94.2  16  16.8  0.155  15,000 (40)  2,000  (44) 
95  16  ND  0.183  12,000 (46)  1,450 (43) 
95.1  12  17.7  0.125  10,000 (30)  1,625 (31) 
95.2  12  18.3  0.176  8,500  (31)  1,700 (35) 
96  12  17.8  0.162  3,000  (42)  4,000  (39) 
<MSCV-IL-11>  12  _+ 4  17.3  +  0.6  0.17  + 0.04  7,500  _  3,700  2,600  _+  1,100 
(45  _+ 8)  (47  _+  12) 
<MSCV-X>  53  _+ 3  20.5  _+  1.4  0.08  +  0.01  3,400  _+ 600  46  +  31 
(48  +  8)  (50  _+ 21) 
<BALB/c>  -  21.1  _+  1.5  0.10  _+ 0.02  2,800  _+  700  215  _+  150 
* Secondary recipients of MSCV-IL-11-infected bone marrow are denoted by the number of the primary recipient followed  by a unique numeric 
extension. MSCV-X and BALB/c values represent the mean and SE of values obtained for six other MSCV transplant mice (as per Table 2 footnotes) 
and for six normal mice, respectively. 
* CFC frequency per 106 cells. 
surface markers. PGMD1 cells express high levels of the leu- 
kocyte common antigen Ly-5 (CD45), high levels of the Fc 
receptor for aggregated IgG (CD32), low levels of the my- 
eloid integrin Mac-1 (CDllb), and low levels of the cell adhe- 
sion molecule ICAM-1 (CD54), but no detectable amounts 
of Ia antigen.  Intravenous inoculation of PGMD1 cells into 
sublethally irradiated  syngeneic BALB/c mice gave rise to my- 
eloid leukemia (four of five mice that received 5  x  106 cells 
developed tumors by 6 too). The fact that in vivo-passaged 
PGMD1 cells maintained their factor dependency upon rein- 
troduction into liquid culture (data not shown) suggests that 
the leukemic disease in 74-series  mice occurs via a paracrine 
mode of growth  stimulation. 
Southern blot analysis of proviral insertion pattern showed 
that DNA from the PGMD1 cell line and spleen DNAs from 
all 74-series  mice contained four predominant bands (Fig.  6 
A). We interpret this result to mean that the myeloprolifera- 
tive disease that developed in this transplant pedigree origi- 
nated in the clonal descendant of a hematopoietic precursor 
harboring four MSCV-IL-11 proviruses. Although the clone 
represented the major MSCV-IL-11-positive cell population 
in the spleen of primary mouse 74, it did not appear to be 
overtly malignant  at this time as indicated by the absence 
of abnormal cells in histologic sections or of atypical colony 
formation in metbylcellulose culture (Table 3). Even after the 
development of frank malignancy,  further clonal evolution 
was  apparently  necessary before successful adaptation  for 
growth in culture. Culture supernatant  from PGMD1 cells 
tested negative for the presence of infectious virus in a sensi- 
tive marker virus mobilization assay (32, 47), arguing against 
insertional mutagenesis by packaging line-generated or spon- 
taneously activated endogenous retroviruses. 
Unlike other IL-3-dependent murine myeloid leukemic cell 
lines (48), PGMD1 cells can be induced to differentiate into 
macrophages and/or granulocytes by GM-CSF or G-CSF (Fig. 
6 D; other data not shown). Analysis of gene expression pat- 
terns during GM-CSF-induced myeloid differentiation  revealed 
upregulated expression of IL-6, Mac-l,  ICAM-1,  andjunB 
1182  Dysregulated  1I.-11 Expression in Mice mRNAs and decreased expression ofc-myb and c-m),c  mRNAs 
(Fig. 6 E). This genetic response is reminiscent of that ob- 
served when autonomously  proliferating M1 murine myeloid 
leukemic cells are stimulated to terminal differentiation by 
IL-6 (49). 
Discussion 
IL-II as a Thrombopoietic Factor in Mice.  To investigate the 
in vivo hematopoietic activities  of IL-11, we generated chi- 
meric mice whose hematopoietic systems had been recon- 
stituted for extended periods of time with genetically modified 
bone marrow cells constitutively expressing IL-11. The major 
effect of high circulating IL-11 levels was a chronic 1.5-fold 
increase in peripheral platelet counts. This finding confirms 
and extends previous reports (4-8) of megakaryocytopoietic 
and thrombopoietic activity oflL-11. In a recent publication 
(8), C57BL/6 mice injected subcutaneously with 1.5 #g of 
IL-11 twice a day for 7 d showed a 1.3-fold elevation in pe- 
ripheral platelet counts compared with vehicle-treated  con- 
trols. In that study, rapid clearance of IL-11 from the circula- 
tion upon cessation of the dosing regimen resulted in platelet 
counts returning to normal values by day 15. Because there 
were no other consistent hematologic changes, the modest 
thrombopoietic  response elicited could have been due to subop- 
timal circulating IL-11 concentrations. In the present series 
of experiments, it is unlikely that IL-11 amounts are limiting 
in this respect. Although spleen megakaryocyte numbers were 
slightly elevated in MSCV-IL-11  mice, observations in sple- 
nectomized mice would suggest that splenic megakaryocyto- 
poiesis does not contribute substantially to the increase in 
peripheral platelets effected by IL-11. Rather, as documented 
previously (8), the higher peripheral platelet counts are prob- 
ably the result of IL-11-induced enhancement of megakary- 
ocyte progenitor numbers and IL-11-stimulated endorepli- 
cation of megakaryocytes in the bone marrow. 
It is noteworthy that sustained high level IL-11 expression 
had little impact on peripheral leukocyte or erythrocyte values, 
the exceptions being a neutrophilic shift in the differential 
and a reduction in mean corpuscular volume, respectively. 
In other work (7, 17), daily administration of IL-11 to mice 
during bone marrow reconstitution accelerated the recovery 
of peripheral leukocytes, mainly neutrophils, in addition to 
platelets.  Moreover,  early recovery of erythrocytes was ob- 
served in another study in mice (50) transplanted with bone 
marrow cells infected with a different IL-11-expressing retro- 
virus.  One interpretation of these results is that IL-11 acts 
synergistically with certain cytokines induced after hemato- 
poietic injury or expressed by the reconstituting cells that 
are not normally present in high concentrations during steady- 
state hematopoiesis. This interpretation would be consistent 
with the demonstrated synergistic interactions between IL- 
11 and multiple cytokines in various in vitro assays and a general 
lack of observed activity when it is used as a single agent 
(2). Future work will investigate the rate of recovery of pe- 
ripheral leukocytes and erythrocytes in transplant recipients 
receiving MSCV-IL-11-infected bone marrow. 
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It should be noted that a transient 1.5-fold increase in leu- 
kocyte counts, primarily due to a sevenfold increase in neu- 
trophils, was seen in B6D2F1 mice that received subcuta- 
neous injections of 4 gg of IL-11 twice a day for 10 d (18). 
As  well,  bone  marrow  cells  from B6D2Ft  mice formed 
significant numbers of macrophage colonies in methylcellu- 
lose when plated into medium containing IL-11 and erythro- 
poietin (9),  indicating that IL-11 can directly support the 
proliferation of some committed macrophage progenitors in 
that mouse strain. A possible reason therefore for the numbers 
of circulating leukocytes remaining relatively unchanged in 
this animal model could be strain-specific differences in IL- 
11 responsiveness. The use of the BALB/c mouse strain might 
explain why blood erythrocyte counts were not markedly 
elevated despite the ability of IL-11 to promote maturation 
of late erythroid progenitors in bone marrow cultures de- 
rived from mice of some other strains (45). This explanation 
is not completely satisfactory,  however, in light of the en- 
hanced splenic hematopoiesis observed.  If anything, the in 
vivo situation is probably complex and other possibilities, 
for example, that constant high level IL-11 expression induces 
activities which are inhibitory to steady-state hematopoiesis 
(51), need also to be considered. Erythrokinetics would also 
be expected to be negatively affected by IL-11-induced alter- 
ations in splenic function and plasma composition (52). 
Pleiotwt~ and Redundancy.  Interestingly, the in vivo effects 
of high sustained concentrations oflL-11 were less like those 
of IL-6 (22) and were more like those of another pleiotropic 
cytokine, leukemia inhibitory factor (LIF) (53). Injection of 
mice with LIF (2 #g three times daily for 14 d) resulted in 
elevated numbers of circulating platelets, a moderate increase 
in spleen weight with an associated rise in the numbers of 
various subsets of splenic progenitors, a small decrease in he- 
matocrit, and thymus atrophy. Nonhematopoietic effects in- 
cluded behavioral  changes (hypermobility and irritability), 
weight loss due to reduction in fatty tissue, distended stomachs, 
and increased erythrocyte sedimentation rate and elevated cal- 
cium/albumin ratios characteristic of the acute phase protein 
reaction. There are differences, however, between IL-11 and 
LIF. For example, LIF appears to be more toxic than IL-11 
since several of the mice injected with LIF died. Moreover, 
chronic exposure of mice to high levels of LIF (plasma con- 
centrations of '-1,000 U/ml) by engraftment of a hemato- 
poietic cell line engineered to express this cytokine resulted 
in the development within 12-70 d of a fatal cachexia (54). 
Nonetheless, the two cytokines dearly share some biologic 
activities. The molecular basis for this overlap is likely to be 
related to the recent finding that both IL-11 and LIF trans- 
duce signals  via a  common transmembrane glycoprotein, 
gp130, originally identified as a component of the IL-6 receptor 
and now known be utilized by two other cytokines, oncostatin 
M and ciliary neurotrophic factor (55, 56). Because the two 
cytokines share a common signal transduction pathway, any 
cell that expresses the binding subunits for IL-11 and LIF 
might be expected to behave similarly  in response to both 
cytokines. It is also possible that the similar in vivo effects 
of high concentrations of IL-11 and LIF are due to one factor 
binding to the high affinity receptor of the other, as has been Figure  6.  Analysis  of myeloid  disease  in 74-series mice. (A) Southern 
blotting of EcoRl-digested  DNA with a neo probe shows donality of 
the disease. (Arrows,  right) The four  diagnostic  proviral integrants  in the 
PGMD1 mydoid  leukemic  cell line  derived  from  spleen  cells  of  quaternary 
recipient 74.1.1.1. See Fig. 3 for abbreviations  used. (/3)  Histologic  section 
of spleen  of tertiary  recipient  74.2.2 showing  obliteration  of  normal  follic- 
ular architecture (x 1,200). (C) Cytospin  preparation of PGMD1 cells 
showing blast morphology.  (D) Cytospin  preparation of PGMD1 ceUs 
grown for 5 d in GM-CSF-cont~ining  medium  showing  macrophages  and 
cells of the granulocytic  lineage. (E) Northern  blot analysis  ofpoly(A)  + 
RNA (1/~g)  from  PGMD1 cells  maintained  in IL,3-supplemented  medium 
or after  GM-CSF  treatment  for 2 d. The blot was sequentially  hybridized 
with probes specific for the Ib11, II~6, Mac-1 j32 integrin subunit, 
ICAM-1, c-myb,  c-myc,junB,  and GAPDH  genes  as described  in Materials 
and Methods. RNA from OTT1 murine  mydoid  cells was included  for 
comparison purposes. 
recently reported for oncostatin M  which can bind to the 
high affinity LIF receptor (57). 
Alternatively, as it has also been demonstrated recently that 
both IL-11 and LIF induce the synthesis of IL-6 by human 
monocyte-macrophages (58, 59), the question is raised whether 
some of the in vivo activities of these cytokines might be 
mediated in part by IL-6. A strong argument for relative lack 
of paracrine IL-6 involvement is the absence of the patho- 
physiology seen  by us  (22)  in mice whose hematopoietic 
systems were reconstituted with bone marrow cells infected 
with a version of the MSCV vector carrying an IL-6 gene. 
Direct evidence that IL-6 does not play a major role in the 
in vivo IL-11 response are the findings that circulating levels 
of endogenous IL-6 were not elevated in MSCV-IL-11 mice 
compared with normal levels and that the abnormally high 
IL-11 levels did not induce detectable amounts of IL-6 mRNA 
in the spleen, a major organ source of IL-6 during endotox- 
emia (60). The fact that plasma samples from MSCV-IL-11 
mice treated with neutralizing antibody to IL-6 stimulated 
T10 cell proliferation more effectively than IL-11 alone does, 
however, indicates the presence of a novel activity  in the plasma 
and leaves open  the possibility that  some of the changes 
observed  might be ascribable to other factors  acting secon- 
darily (61). 
IL-11 and Malignant Growth.  IL-11 was originally identified 
as a factor with mitogenic activity for IL-6-dependent mu- 
rine Tl165 plasmacytoma ceils (4). We and others (62,  and 
our unpublished results) observed that IL-11 also stimulates 
the proliferation of IL-6-dependent murine B9 hybridoma 
cells. In the absence of IL-6, IL-11 poorly supports the growth 
of either cell line and the vast majority of the cells die by 
apoptosis (63). The T10 derivative of Tl165 ceils was estab- 
lished by selection for a variant that would grow in medium 
supplemented with only IL-11 (34).  We showed that IL-11 
can act as an autocrine growth factor for both IL-11-depen- 
dent T10 cells and IL-11-responsive  B9 cells. The in vitro 
mechanism of action of IL-11 on these IL-6-dependent mu- 
rine B-lineage ceils appears to be direct and not due to the 
1184  Dysregulated  IL-11 Expression in Mice induction of endogenous IL-6. Previous results demonstrated 
that acquisition of autostimulatory IL-6 production enhanced 
the tumorigenicity of other IL-6-dependent murine plasmacy- 
toma/hybridoma cells (64, 65). The acquisition of the ability 
to produce autogenous IL-11 similarly potentiated the tumor- 
igenicity of T10 and B9 cells, although, in the case of B9, 
the effect was less pronounced owing to the ready ability of 
these cells to grow in vivo in response to host IL-6 (42). These 
findings raise the possibility that IL-11 might be involved, 
conceivably in an autocrine manner, in the in vivo growth 
of some murine B cell tumors. At this time, however,  the 
relevance of these observations to human tumor biology is 
unclear.  In the human system, IL-6 has been demonstrated 
to promote the growth of multiple myeloma cells, either in 
a paracrine or autocrine fashion, but IL-11 has not yet been 
found to be a myeloma growth factor (34). 
In contrast to the situation with established cell lines, ac- 
cumulated data has indicated that autocrine stimulation alone 
is  insufficient  to  transform primary cells (66).  Prolonged 
growth factor expression in vivo causes hyperplasia that in- 
frequently leads to neoplastic transformation (67, 68). In this 
series of transplants involving 10 primary and 20 secondary 
recipients of MSCV-IL-11-infected bone marrow, myeloid 
leukemia developed in  two  secondary recipients  of bone 
marrow from the same donor. By comparison, none of over 
300 BALB/c mice transplanted in our laboratory with bone 
marrow cells infected with other recombinant retroviruses 
have developed a myeloid malignancy (22,  32, and our un- 
published results). As the PGMD1 leukemic cell line requires 
a source of IL-3 for propagation, however, it has been difficult 
to demonstrate a direct stimulatory role for IL-11 (69). Some 
degree of growth enhancement by IL-11 is assumed based 
on studies with normal progenitor cells (9) and more recent 
results showing that IL-11 acts synergistically  with IL-3 or 
GM-CSF in stimulating the in vitro growth of the blast cells 
from patients with acute myeloblastic leukemia (70). On the 
other hand, since a paracrine mechanism of growth promo- 
tion appears to be operating in vivo, it is possible that consti- 
tutive IL-11 synthesis by the leukemic cells might stimulate 
production of the necessary growth factors by host cells (71). 
In any event, the MSCV-IL-11-marked clone represented the 
major population of donor cells in the spleen of primary mouse 
74 but did not appear to be overtly malignant at that time. 
This suggests that whereas IL-11-supported expansion of pro- 
genitors might have initiated the process (72), secondary le- 
sions  were presumably necessary  for progression to  frank 
malignancy (73). 
The Bone Marrow Chimera Approach.  We have demon- 
strated efficient infection of hematopoietic stem cells, precursors 
capable of long-term multilineage reconstitution of lethally 
irradiated primary and secondary recipients,  by functional 
MSCV-IL-11 viruses. Although we have not shown that the 
same MSCV-IL-11 provirus is transcriptionally active in both 
myeloid and lymphoid progeny of a single stem ceil, the main- 
tenance of high level expression  of a nonselectable  gene in 
vivo for (the equivalent of) at least 7 mo makes this in vivo 
gene transfer strategy a practical alternative to transgenic tech- 
nology for analysis of gene function in the hematopoietic 
system. 
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